85 related articles for article (PubMed ID: 445512)
21. Adriamycin-induced cardiomyopathy.
Compr Ther; 1979 Apr; 5(4):7. PubMed ID: 445992
[No Abstract] [Full Text] [Related]
22. [Chronic cardiotoxicity of adriamycin and the possible prevention by coenzyme Q10 in rabbits (author's transl)].
Sawada H; Tashima M; Donomae N; Eguchi T; Uehara N; Shirakawa S; Yamagishi M; Nakamura T; Uchino H; Konishi T; Okazaki H; Matsuyama E
Nihon Gan Chiryo Gakkai Shi; 1979 Apr; 14(2):143-51. PubMed ID: 448221
[No Abstract] [Full Text] [Related]
23. Delayed and progressive myocardial lesions after adriamycin administration in the rabbit.
Jaenke RS
Cancer Res; 1976 Aug; 36(8):2958-66. PubMed ID: 1277204
[TBL] [Abstract][Full Text] [Related]
24. L-carnitine ameliorates doxorubicin-induced nephrotic syndrome in rats.
Boonsanit D; Kanchanapangka S; Buranakarl C
Nephrology (Carlton); 2006 Aug; 11(4):313-20. PubMed ID: 16889571
[TBL] [Abstract][Full Text] [Related]
25. A comparative electron microscopic study of aclacinomycin and adriamycin cardiotoxicities in rabbits and hamsters.
Wakabayashi T; Oki T; Tone H; Hirano S; Omori K
J Electron Microsc (Tokyo); 1980; 29(2):106-18. PubMed ID: 6933206
[No Abstract] [Full Text] [Related]
26. Doxorubicin-induced cardiomyopathy.
Lipshultz SE; Grenier MA; Colan SD
N Engl J Med; 1999 Feb; 340(8):653-4; author reply 655. PubMed ID: 10049085
[No Abstract] [Full Text] [Related]
27. [Influence of trifluoperazine and flunarizine on the late myocardial toxicity of doxorubicin].
Favalli L; Lanza E; Rozza A; Villani F; Poggi P; Piccinini F; Monti E
Cardiologia; 1987 Sep; 32(9):1065-9. PubMed ID: 3690600
[No Abstract] [Full Text] [Related]
28. Cardiomyopathy and other chronic toxic effects induced in rabbits by doxorubicin and possible prevention by coenzyme Q10.
Domae N; Sawada H; Matsuyama E; Konishi T; Uchino H
Cancer Treat Rep; 1981; 65(1-2):79-91. PubMed ID: 7226168
[TBL] [Abstract][Full Text] [Related]
29. Prenylamine inhibition of adriamycin-induced myocardiopathy.
Milei J; Boveris A; Molina H; Llesuy S; Storino R; Milei SE
Acta Cardiol; 1985; 40(4):383-96. PubMed ID: 3876672
[TBL] [Abstract][Full Text] [Related]
30. [Gene expression and protein synthesis in the normal heart muscle and in adriamycin cardiomyopathy].
Zähringer J
Fortschr Med; 1983 May; 101(17):805-7. PubMed ID: 6862340
[No Abstract] [Full Text] [Related]
31. [Prevention of cardiotoxicity of doxorubicin (Adriamycin) using cardioxane (ICRF-187, dexrazoxane) in the combination chemotherapy of disseminated breast cancer].
Gershanovich ML; Moiceenko VM; Orlova RV
Vopr Onkol; 1993; 39(1-3):26-32. PubMed ID: 8073671
[TBL] [Abstract][Full Text] [Related]
32. [Fatal myocardiopathy due to adriamycin in spite of a reportedly non-dangerous cumulative dose].
Battin J; Richir C; Bui NB; Hehunstre JP; Abecassis S
Ann Pediatr (Paris); 1989 Feb; 36(2):136-40. PubMed ID: 2930128
[TBL] [Abstract][Full Text] [Related]
33. Novel OCTN2 mutations: no genotype-phenotype correlations: early carnitine therapy prevents cardiomyopathy.
Lamhonwah AM; Olpin SE; Pollitt RJ; Vianey-Saban C; Divry P; Guffon N; Besley GT; Onizuka R; De Meirleir LJ; Cvitanovic-Sojat L; Baric I; Dionisi-Vici C; Fumic K; Maradin M; Tein I
Am J Med Genet; 2002 Aug; 111(3):271-84. PubMed ID: 12210323
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
35. [Monitoring cardiotoxicity during antineoplastic chemotherapy].
Jurga L; Ponist J; Jonás P; Berc A; Misurová E
Cesk Radiol; 1987 Jan; 41(1):28-37. PubMed ID: 3815581
[No Abstract] [Full Text] [Related]
36. Antagonism of doxorubicin cardiotoxicity by carnitine is specific of the L-diasteroisomer.
Maccari F; Ramacci MT
Biomedicine; 1981 May; 35(2):65-7. PubMed ID: 7260239
[TBL] [Abstract][Full Text] [Related]
37. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
Mohamed HE; Asker ME; Ali SI; el-Fattah TM
J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
[TBL] [Abstract][Full Text] [Related]
38. Combined cardiotoxicity of adriamycin and x-radiation.
Fajardo LF; Eltringham JR; Steward JR
Lab Invest; 1976 Jan; 34(1):86-96. PubMed ID: 1246126
[TBL] [Abstract][Full Text] [Related]
39. Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.
Pinkel D; Camitta B; Kun L; Howarth C; Tang T
Med Pediatr Oncol; 1982; 10(5):483-8. PubMed ID: 6292680
[TBL] [Abstract][Full Text] [Related]
40. Doxorubicin cardiomyopathy: underlying cause of interferon-induced cardiac dysfunction?
Geffen DB; Liel-Cohen N
Isr Med Assoc J; 2007 Sep; 9(9):690; author reply 690-1. PubMed ID: 17939640
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
